Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1750 | Home-based exercise Wiki | 1.00 |
| drug4253 | Vitamin D3 Wiki | 0.41 |
| drug4335 | Zinc Wiki | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
Description: Time to negative RT-PRC result indicating that patient is no longer infective
Measure: Time to Non-Infectivity by RT-PCR Time: 6 monthsDescription: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score) Time: 6 monthsDescription: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score) Time: 6 monthsDescription: Patients will have serum stored for titer testing to compare antibody levels over time
Measure: Efficacy of Treatment as measured by Titer Time: 6 monthsDescription: Number of patients testing negative for SARS-CoV-2 by RT-PCR after 10 days of treatment
Measure: Efficacy of Treatment as measured by RT-PCR Time: 10 daysDescription: Blood D-Dimer levels
Measure: Safety of Treatment as Measured by D-Dimer Time: 6 MonthsDescription: Blood Pro-Calcitonin levels
Measure: Safety of Treatment as Measured by Pro-Calcitonin Time: 6 MonthsDescription: Blood CRP levels
Measure: Safety of Treatment as Measured by C-Reactive Protein Time: 6 MonthsDescription: Blood ferritin levels
Measure: Safety of Treatment as Measured by Ferritin Time: 6 MonthsDescription: Blood enzyme levels
Measure: Safety of Treatment as Measured by Liver Enzymes Time: 6 MonthsDescription: CBC
Measure: Safety of Treatment as Measured by Complete Blood Count Time: 6 MonthsDescription: Blood electrolytes
Measure: Safety of Treatment as Measured by Electrolyte Levels Time: 6 MonthsDescription: Presence or absence of Grade 3 or high treatment related adverse events
Measure: Safety of Treatment as Measured by Treatment Related Adverse Events Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports